RYE BROOK, N.Y., May 30, 2025 – During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting oncologists and researchers from around the world come together to share data and new solutions to improve outcomes for people with blood and other cancers.
Leukemia & Lymphoma Society (LLS) supported researchers will present study results on various blood cancers touching on topics such as treatment efficacy and safety, as well as medical debt and effective communications with patients about clinical trials. Several current and former partners of the LLS venture philanthropy, the Therapy Acceleration Program (TAP), will also present the latest updates from their ongoing trials.
“Gatherings of oncologists and researchers who are committed to improving the lives of people with cancer provide an opportunity to share knowledge and create connections that accelerate discovery,” says Lore Gruenbaum, Ph.D., chief scientific officer, The Leukemia & Lymphoma Society. “LLS is proud of our legacy in providing support that connects research from bench to bedside and I’m looking forward to hearing all the latest at ASCO.”
Following is an overview of data from LLS that will be presented at ASCO:
Investing in Blood Cancer Research to Change the Standard of Care
More than 10 abstracts, representing research supported by LLS’s Therapy Acceleration Program, Career Development Program, Health Services Research Program and Equity in Access Research Grants will present data on several types of blood cancer and assess cancer care.
Title & Abstract Number | Presentation Type | LLS Research Program |
Oral Abstract Session | Therapy Acceleration Program | |
Oral Abstract Session | Therapy Acceleration Program | |
Oral Abstract Session | Therapy Acceleration Program | |
Rapid Oral Abstract Session | Therapy Acceleration Program | |
Poster Session | Health Services Research | |
Poster Session | Health Services Research | |
Poster Session | Equity in Access | |
Poster Session | Career Development Program | |
Poster Session | Career Development Program | |
Poster Session | Career Development Program | |
Rapid Oral Abstract Session | Special |
LLS Chief Scientific Officer Lore Gruenbaum, Ph.D., is available to provide perspectives on pivotal blood cancer data presented at the 2025 ASCO Annual Meeting.
LLS Vice President, Therapy Acceleration Program Blaine Robinson, Ph.D., is available to discuss TAP findings.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the global leader and innovator in creating a world without blood cancer. The LLS mission: Cure blood cancer and improve the quality of life of all patients and their families. LLS is focused on accelerating research, providing free support and services, and advocating for policies to ensure access to quality, affordable care. For more than 75 years, LLS has been helping blood cancer patients live longer, better lives.
Founded in 1949, LLS has regions throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
For additional information, visit lls.org/lls-newsnetwork. Follow us on Facebook, X, Instagram, LinkedIn and TikTok.